FDA tags J&J's Nizoral with new safety risks; Reckitt's health unit powers sales growth; Pricey new drugs to fuel big MS market growth;

@FiercePharma: Pfizer to split operations three ways. Story | Follow @FiercePharma

@EricPFierce: EU doesn't like smell of Germany's exemption to financially struggling drugmakers from paying drug rebates. More | Follow @EricPFierce

@CarlyHFierce: 's former head of China biz will be returning to China to assist with bribery probe. 18 more reportedly detained there. | Follow @CarlyHFierce

> The FDA flagged an increased risk of serious liver injuries and adrenal gland problems with Johnson & Johnson's ($JNJ) fungal treatment Nizoral, generically known as ketoconozale, and said it should not be used as a first-line treatment. Report (sub. req.)

> Buoyed by its expanding health division, Reckitt Benckiser said its 2013 growth will hit the upper end of its targets, with revenues so far this year up 6%, to £5 billion, or $7.68 billion. Report

> The market for multiple sclerosis drugs is expected to grow by 10% a year through 2018, peaking at almost $21 billion that year, a market study found, driven by newly launched, pricey drugs. Report

> Pfizer ($PFE) is among the major companies that lobbied U.S. lawmakers during the second quarter on trade issues with India, disclosures show. Report

> Alexion Pharmaceuticals ($ALXN) plans to create 50 new jobs at a new office in Ireland, along with ongoing plants for a new global supply-chain facility in the country. Report

> UBS upgraded India's Ranbaxy Laboratories to 'buy' from 'sell' after its shares took a dive on regulatory concerns. Report

> It takes 10 years for data proving treatments ineffective to translate into changes in clinical practice, a new study found. Report

> Cadila Healthcare, a unit of Zydus Pharmaceuticals, launched its commercial operations in Mexico City. Report

Medical Device News

@FierceMedDev: Check out last week's special report: Top 10 Med Tech Investments of Q2. Report | Follow @FierceMedDev

@MarkHFierce: ReVision optics closed $55M in new equity financing. Medical Device financing shows some signs of life. Release | Follow @MarkHFierce

@DamianFierce: Quintiles has signed up to help Ascendancy Healthcare cash in on the Chinese pharma boom. More | Follow @DamianFierce

 @MichaelGFierce: NeuroSigma to begin PhIII epilepsy device trial. Item | Follow @MichaelGFierce

> Glass implant envisioned to promote leg, arm bone repairs. More

> J&J leads ReVision Optics' $55M financing round. Story

Biotech News

@FierceBiotech: ICYMI: Scripps spinout aTyr grabs $59M in venture deals with a public twist. Story | Follow @FierceBiotech

@RyanMFierce: Add Five Prime to the biotech IPO queue, hunting for $60M public debut with backers from Pfizer, GlaxoSmithKline. Report | Follow @RyanMFierce

@EmilyMFierce: FDA notes 'technical deficiencies' in Chelsea's drug filing. Article | Follow @EmilyMFierce

> Scripps spinout aTyr grabs $59M in venture deals with a public twist. More

> Perrigo to take over Elan for $8.6B. Report

> Celgene spends $100M for option to buy myeloma drug developer Acetylon. News

CRO News

> Swiss CRO Psi reaches into South Africa. Item

> Quintiles teams up with Ascendancy in China. News

> Icon ticks up guidance as revenue leaps another 21%. Report

> CRA buys Comprehensive Clinical's late-phase biz. Article

> AMRI working to get out from under FDA warning. More

Biotech IT News

> Medidata shares soar on another record quarter in Q2. Item

> AstraZeneca adds software from Dotmatics to virtual neuroscience group. Article

> Novo Nordisk among latest to join pharma flock on Twitter. Story

> Sanofi returns to the crowdsourcing well for diabetes app. More

> NIH earmarks $96M for multiyear effort to maximize value of Big Data. Report

And Finally... People who feel helpless to change their circumstances are more likely to see their stress turn into disease, scientists found. Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.